Biogen Inc. is a leader in discovering, developing, manufacturing, and delivering innovative therapies for neurological and neurodegenerative diseases. The portfolio includes treatments such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS), SPINRAZA for spinal muscular atrophy, and FUMADERM for plaque psoriasis. Additionally, the company offers BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. Furthermore, RITUXAN is provided for non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA also targets non-Hodgkin's lymphoma and CLL, while GAZYVA treats CLL and follicular lymphoma. OCREVUS is available for relapsing MS and primary progressive MS, alongside various anti-CD20 therapies. The company's pipeline includes promising candidates such as BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 for Alzheimer's disease and dementia; and BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 targeting neuromuscular disorders. Biogen also develops treatments for Parkinson's disease, neuropsychiatric conditions, immunological diseases, acute neurology, and neuropathic pain, alongside a range of biosimilars under development. The company has established collaborations and license agreements with notable entities such as Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, and Genentech, Inc. Biogen Inc. earned an interest income of $87,800,000.00 showcasing its financial investments, and reported an income before tax of $1,401,500,000.00 demonstrating its pre-tax profitability. The net income ratio is 0.13 reflecting the company's profitability margin, while the EBITDA is $3,100,600,000.00 a key indicator of its operational profitability. Additionally, the operating income ratio is 0.19 indicating solid operational performance. The stock is reasonably priced at $142.50 appealing to a broad range of investors. With a high average trading volume of 1,994,300.00 the stock indicates strong liquidity, and Biogen holds a mid-range market capitalization of $28,432,367,336.00 marking it as a steady performer in the market. It is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape, and it operates within the Healthcare sector, driving innovation and growth. This combination of factors makes Biogen an attractive option for stakeholders seeking opportunities in the pharmaceutical sector, particularly in neurological treatment advancements.